Strong close today, page-30

there are 400mill shares. market cap is about $150 mill (at 37 cents). revenues 'was' $5 mill, but is projected to be now $20 mill (on signed contracts); but it aint about reveune, it is about cash flow, profitability and ability to grow.

if they end up as eps of 1 cent (as Canaccord project) in FY21, you can easily say 'at 3% profit, the share should be 33 cents'.

so I think there is a base for mid 30s; the growth is ON TOP OF THAT - so you get 'some number' above mid 30s - depending upon what growth you expect

I think Mr Market thinks this is a covid share; that is not true; it is a share that teams with any needed bio; covid accelerates it! but note in the presentations they talk about using the product in VET science... and... and... and many other applications and partners and uses.